Application of propofol target controlled Infusion combined with different dose of etomidate in painless gastrointestinal endoscopy: a prospective, randomized, controlled study

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100044884

Enrollment

Unknown

Registered

2021-03-31

Start date

2021-04-12

Completion date

Unknown

Last updated

2022-11-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

gastrointestinal disease

Interventions

propofol group:Propofol target controlled infusion

Propofol target-controlled infusion combined with 0.1mg/kg etomidate group:0.1mg/kg etomidate plus propofol TCI

Propofol target-controlled infusion combined with 0.15mg/kg etomidate group:0.15mg/kg etomidate plus propofol TCI

Eligibility

Sex/Gender

All

Age

18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1.Scheduled for painless gastrointestinal endoscopy; 2.Aged 18-75 years; 3.With American Society of Anesthesiologists (ASA) physical status I to III; 4.With Mallampati classification I or II.

Exclusion criteria

Exclusion criteria: 1.With circulation dysfunction,liver dysfunction,kidney dysfunction and other important organ dysfunction; 2.Allergic to propofol or fat emulsion; 3.A history of drug abuse; 4.With acute upper respiratory infection; 5.With Obstructive sleep apnea hypopnea syndrome or body mass index, BMI>= 28kg/m2; 6.With adrenal insufficiency.

Design outcomes

Primary

Measure	Time frame
blood pressure;concentration of propofol;	—

Secondary

Measure	Time frame
heart rate;Oxygenation;Incidence of hypotension;Incidence of bradycardia;recovery time;Induction time;Incidence of injection pain;Incidence of postoperative nausea and vomiting;Patients' and physicians' satisfaction of sedation;	—

Countries

China

Contacts

Public ContactLuo Huirong

Fujian Medical University Union Hospital

470797962@qq.com+86 17706918361

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026